← Back to Search

Alkylating Agent

Nivolumab for Multiple Myeloma

Phase 2
Waitlist Available
Research Sponsored by Andrew Yee, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

This trial is testing a new combination treatment for multiple myeloma that has relapsed or become resistant to other treatments.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective Response Rate (ORR)
Secondary outcome measures
Progression Free Survival

Trial Design

1Treatment groups
Experimental Treatment
Group I: Nivolumab and IxazomibExperimental Treatment4 Interventions
- Participants will receive Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone on a 28-day cycle. Oral: Ixazomib given weekly on days 1, 8, 15 Dexamethasone given weekly during cycle Infused: Nivolumab given once per cycle Cyclophosphamide given on days 1, 8, 15 during cycle
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nivolumab
FDA approved
Ixazomib
FDA approved
Dexamethasone
FDA approved
Cyclophosphamide
FDA approved

Find a Location

Who is running the clinical trial?

Andrew Yee, MDLead Sponsor
1 Previous Clinical Trials
43 Total Patients Enrolled
1 Trials studying Multiple Myeloma
43 Patients Enrolled for Multiple Myeloma
Bristol-Myers SquibbIndustry Sponsor
2,650 Previous Clinical Trials
4,130,830 Total Patients Enrolled
88 Trials studying Multiple Myeloma
30,531 Patients Enrolled for Multiple Myeloma
Takeda Pharmaceuticals North America, Inc.Industry Sponsor
57 Previous Clinical Trials
8,961 Total Patients Enrolled
~0 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top